🔎 Trials Near Me

Acasă › Limfom Burkitt › Utah

Studii clinice pentru Limfom Burkitt în Utah

7 studii pentru Limfom Burkitt caută participanți în Utah.

Orașe în Utah

Text oficial al studiului (în engleză)

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Huntsman Cancer Institute/University of Utah, Salt Lake City
În curs de recrutareFaza 3
Vârste de la 18 la 39 · Toate sexele · Actualizat 2 oct. 2026 · NCT03150693

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Intermountain - Primary Children's Hospital ( Site 1014), Salt Lake City
În curs de recrutareFaza 1/2
6 Months – 25 Years · Toate sexele · Actualizat 17 sept. 2026 · NCT06395103

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

  • Primary Children's Hospital, Salt Lake City
În curs de recrutareFaza 1
Vârste de la 0 la 18 · Toate sexele · Actualizat 16 sept. 2026 · NCT06173518

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Primary Children's Hospital, Salt Lake City
În curs de recrutareFaza 2
Vârste de la 1 la 30 · Toate sexele · Actualizat 1 sept. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Primary Children's Hospital, Salt Lake City
În curs de recrutareFaza 3
365 Days – 25 Years · Toate sexele · Actualizat 25 aug. 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Primary Children's Hospital, Salt Lake City
În curs de recrutareFaza 2
Vârste de la 7 la 25 · Toate sexele · Actualizat 19 aug. 2026 · NCT05082519

Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.